上客户端，和病友交流
点击下载
返回
肾癌
Philip Philip M.D., Ph.D., F.R.C.P

Philip Philip M.D., Ph.D., F.R.C.P

外科
Karmanos cancer center

擅长疾病

临床新药咨询

通过咨询找到适合自己的药物

专家会诊咨询

专业、及时的一对一咨询

如果您的问题未能解决，您还可以选择：

医学顾问

极速问诊

2万名名医
7*24小时为您匹配
1对1

找专家

肿瘤专科专家
对症找医专科专治

专家介绍

2015-06-17 15:432643
 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Gastrointestinal Oncology 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Adrenal Cancer 
Anal Cancer 
Ampullary and periampullary cancers 
Appendix Cancer 
Bile Duct Cancer 
Cancer of unknown origin 
Carcinoid Tumors 
Cholangiocarcinoma 
colon Cancer 
Esophageal Cancer 
Gall Bladder Cancer 
Gastroesophageal Junction (GEJ) 
Gastrointestinal Stromal Tumors (GIST) 
Liver Cancer 
Neuroendocrine Tumors 
Pancreatic Cancer 
Pancreatic Neuroendocrine Tumor (pNET) 
Peritoneum and psuedomyxoma peritonii 
Rectal Cancer 
Small Intestine Cancer 
Stomach Cancer 

·         Contact Info

·         Email:
philipp@karmanos.org

 

来自 <http://www.karmanos.org/physicians/Philip-Philip?Disease=229&PageIndex=0&SortDirection=1>

 

·         Education

·         Fellowship
Clinical Research Fellow and Honorary Registrar, Department of Clinical Pharmacology and the Lymphoma Unit, Guy's Hospital Medical School, University of London, London, United Kingdom
Fellowship
Medical Oncology, MD Anderson Cancer Center, Houston, Texas
Medical School
University of Baghdad, College of Medicine
Residency
Resident in Internal Medicine, Al-Taji Hospital, Baghdad, Iraq
Residency
Senior Resident in Internal Medicine, Medical City Teaching Hospital, University of Baghdad, Baghdad, Iraq
Graduate Training
Clinical Pharmacology & Pharmacogenetics, University of London

·         Professional Memberships/Associations

·         European Organization for Research and Treatment of Cancer (Pharmacology and Molecular Mechanisms Group) 
American Association for Cancer Research 
American Society of Clinical Oncology 
American Society of Clinical Pharmacology and Therapeutics 
Southwest oncology Group (Leader – Pancreas Cancer Subcommittee and member of the Steering Committee for GI Cancer) 
American Pancreatic Association 

·         Board Certifications

·         American Board of Internal Medicine
Medical Oncology

·         Clinical Interests

·         Medical Oncologist 

·         Research Interests

·         Novel therapies for GI cancers (liver, pancreas, biliary, colon, rectum, carcinoid, GIIST, stomach, esophagus, anal) 

·         Profile

·         Philip is a Professor of Medicine at Wayne State University School of Medicine and a Clinical Professor of oncology at the Barbara Ann Karmanos Cancer Institute in Detroit, MI. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. Philip Philip’s primary research focus is the oversight of clinical trials of novel therapeutic agents and therapeutic combinations on patients with pancreatic, gastro-esophageal, liver, and colorectal cancer. He is actively involved in Phase I and II clinical trials. Philip has received numerous awards, including the Wayne State University Medical School Teaching Award (1999, 2004), and Outstanding Instructor in oncology Award (2001). He belongs to numerous professional organizations including the American pancreatic Association and the American Society of Clinical Oncology. Philip serves on the Editorial Board of the Internet Journal of oncology and Community oncology and reviews for multiple journals, including the Journal of Clinical oncology and the European Journal of Cancer. He has authored over 70 articles in peer-reviewed journal, 7 book chapters and many invited review articles. Philip received his BA (1971, American Jesuit Fathers College, Baghdad, Iraq), MD (1977, University of Baghdad College of Medicine), and PhD in Clinical Pharmacology and Pharmacogenetics (1986, University of London, UK). He trained in oncology at the University of Oxfor(UK) and the MD Anderson Cancer Center.

·         Awards

·         Best Doctors of America
Wayne State University School of Medicine Teaching
2001 Outstanding Instructor in oncology Award, WSU
Voted one of Best Doctors Inc. 2011-2014 Best Doctors of the Year

·         Publications

·         Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2011 May;2(5):378-92. PMID: 21623005; PMCID: PMC3248191. Authors: Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM.
Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am J Transl Res. 2011 Aug 15;3(4):374-82. Epub 2011 Jul 26. PubMed PMID: 21904657; PubMed Central PMCID: PMC3158739. Authors: Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S, Philip PA, Mohammad RM, Sarkar FH.
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2011 Sep 27. doi: 10.1002/cncr.26556. [Epub ahead of print] PMID: 21953248. Authors: Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C.
Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol. 2011 Dec 29. doi: 10.1002/jcp.24036. [Epub ahead of print] PMID: 22213426. Authors: Ali S, Banerjee S, Logna F, Bao B, Philip PA, Korc M, Sarkar FH.
Locally advanced pancreatic cancer: wher should we go from here? J Clin Oncol. 2011 Nov 1;29(31):4066-8. Epub 2011 Oct 3. PMID: 21969514. Author: Philip PA.

 

1. 添加医学顾问微信，扫描☟二维码

2. 备注【癌种】进病友群

扫描预约专家问诊

专家科普

同类全球会诊
合作伙伴：